Search
Rindopepimut
go.drugbank.com/drugs/DB05374InvestigationalThe US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.
Chromium picolinate
go.drugbank.com/drugs/DB11255ApprovedChromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss.
Squalene
go.drugbank.com/drugs/DB11460ApprovedInvestigationalVet approvedWithdrawnSqualene is investigated as an adjunctive cancer therapy.
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]
Etifoxine
go.drugbank.com/drugs/DB08986ApprovedWithdrawnIt is more effective than lorazepam as an anxiolytic, and has fewer side effects. Etifoxine has been associated with acute liver injury.
Ceforanide
go.drugbank.com/drugs/DB00923ApprovedMany coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species
Papaverine
go.drugbank.com/drugs/DB01113ApprovedInvestigationalIt is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation.
Naloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult pati...
Loteprednol
go.drugbank.com/drugs/DB00873ApprovedInvestigationalWithdrawnLoteprednol is a corticosteroid. A more commonly used formulation of loteprednol is its ester, loteprednol etabonate.
LErafAON
go.drugbank.com/drugs/DB04973InvestigationalPhase I/II trials commenced in March 2001 and were ongoing as of June 2003.